UY35183A - Composición farmacéutica oftalmológica tópica que contiene regorafenib - Google Patents

Composición farmacéutica oftalmológica tópica que contiene regorafenib

Info

Publication number
UY35183A
UY35183A UY0001035183A UY35183A UY35183A UY 35183 A UY35183 A UY 35183A UY 0001035183 A UY0001035183 A UY 0001035183A UY 35183 A UY35183 A UY 35183A UY 35183 A UY35183 A UY 35183A
Authority
UY
Uruguay
Prior art keywords
typical
pharmaceutical composition
composition containing
ophthalmological pharmaceutical
ophthalmological
Prior art date
Application number
UY0001035183A
Other languages
English (en)
Inventor
Dr Georges Von Degenfeld
Dr Joerg Keldenich
Dr Michael Böttger
Dr Julia Freundlieb
Dr Claudia Hirth-Dietrich
Dr Jürgen Klar
Dr Uwe Muenster
Dr Andreas Ohm
Dr Annett Richter
Dr Bernd Riedl
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of UY35183A publication Critical patent/UY35183A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas oftalmológicas que contienen regorafenib, un hidrato, solvato, metabolito o sal aceptables desde el punto de vista farmacéutico del mismo o un polimorfo del mismo pero sin sílice hidrofóbica y su procedimiento de preparación y su uso para tratar trastornos oftalmológicos
UY0001035183A 2012-12-21 2013-12-11 Composición farmacéutica oftalmológica tópica que contiene regorafenib UY35183A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12198892 2012-12-21

Publications (1)

Publication Number Publication Date
UY35183A true UY35183A (es) 2014-07-31

Family

ID=47458742

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035183A UY35183A (es) 2012-12-21 2013-12-11 Composición farmacéutica oftalmológica tópica que contiene regorafenib

Country Status (27)

Country Link
US (2) US20140179745A1 (es)
EP (1) EP2934481A1 (es)
JP (1) JP2016507505A (es)
KR (1) KR20150100670A (es)
CN (1) CN104955443A (es)
AP (1) AP2015008493A0 (es)
AR (1) AR094104A1 (es)
AU (1) AU2013364004A1 (es)
BR (1) BR112015014078A2 (es)
CA (1) CA2895804A1 (es)
CL (1) CL2015001701A1 (es)
CR (1) CR20150327A (es)
CU (1) CU20150063A7 (es)
DO (1) DOP2015000155A (es)
EA (1) EA201500669A1 (es)
EC (1) ECSP15026386A (es)
IL (1) IL238791A0 (es)
MA (1) MA38215A1 (es)
MX (1) MX2015007488A (es)
PE (1) PE20151784A1 (es)
PH (1) PH12015501407A1 (es)
SG (1) SG11201503838WA (es)
TN (1) TN2015000280A1 (es)
TW (1) TW201431568A (es)
UY (1) UY35183A (es)
WO (1) WO2014100797A1 (es)
ZA (1) ZA201505196B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458031A4 (en) * 2016-05-16 2020-01-22 Delivra Inc. TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF CELECOXIB AND THEIR USE IN THE TREATMENT OF CELCOXIB-SENSITIVE DISEASES AND CONDITIONS
CN112834485B (zh) * 2021-02-07 2022-03-29 西南交通大学 激光诱导击穿光谱元素定量分析的一种非定标方法
KR102413226B1 (ko) 2021-08-26 2022-06-23 충북대학교 산학협력단 레고라페닙을 유효성분으로 포함하는 항노화 조성물
KR20230166353A (ko) 2022-05-30 2023-12-07 (주) 레비레스코 감태 추출물, 귤피 추출물, 및 녹차 추출물을 유효성분으로 포함하는 자외선에 대한 세포 보호용 또는 mmp-1 발현 억제용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001834A1 (es) * 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
AU2006244244B2 (en) 2005-05-10 2010-11-04 Alcon, Inc. Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
BRPI0606172A2 (pt) 2005-06-08 2009-06-02 Targegen Inc métodos e composições para o tratamento de distúrbios oculares
WO2007064752A2 (en) 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
WO2007068382A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl urea for treating inflammatory skin. eye and/or ear diseases
US20070149593A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP3165606A1 (en) 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
CA2768237A1 (en) 2009-07-16 2011-01-20 Glaxo Wellcome Manufacturing Pte Ltd Treatment method
PE20141031A1 (es) * 2011-06-28 2014-08-21 Bayer Healthcare Llc Composicion farmaceutica oftalmologica topica que contiene regorafenib

Also Published As

Publication number Publication date
CR20150327A (es) 2015-09-14
SG11201503838WA (en) 2015-07-30
MA38215A1 (fr) 2017-01-31
IL238791A0 (en) 2015-06-30
ECSP15026386A (es) 2016-01-29
JP2016507505A (ja) 2016-03-10
CA2895804A1 (en) 2014-06-26
AP2015008493A0 (en) 2015-05-31
MX2015007488A (es) 2015-09-04
TW201431568A (zh) 2014-08-16
CL2015001701A1 (es) 2015-10-16
US20140179745A1 (en) 2014-06-26
DOP2015000155A (es) 2015-08-31
EP2934481A1 (en) 2015-10-28
AR094104A1 (es) 2015-07-08
AU2013364004A1 (en) 2015-06-04
EA201500669A1 (ru) 2015-12-30
PE20151784A1 (es) 2015-11-25
KR20150100670A (ko) 2015-09-02
CN104955443A (zh) 2015-09-30
ZA201505196B (en) 2017-11-29
PH12015501407A1 (en) 2015-09-07
BR112015014078A2 (pt) 2018-05-15
TN2015000280A1 (en) 2016-10-03
CU20150063A7 (es) 2015-11-27
US20150328145A1 (en) 2015-11-19
WO2014100797A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
CR20150327A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
BR112018069782A2 (pt) composição farmacêutica de dapagliflozina
BR112013018781A2 (pt) composto derivado de piridona, e, composição farmacêutica
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
DOP2015000049A (es) Composición farmacéutica recubierta que contiene regorafenib
IN2013MU03838A (es)